🚀 Pharmidex at Medical Technology UK 2025! 🚀
March 12, 2025

We’re excited to announce that Martin Barrett, our Head of Business Development, will be attending Medical Technology UK 2025 on 12-13 March at Coventry Building Society Arena! 🏥💡


Martin is looking forward to connecting with fellow industry leaders, researchers, and innovators to explore new collaborations and opportunities in advancing drug discovery and development. If you're attending, don’t miss the chance to meet him and discuss how Pharmidex can support your projects!


📅 Event: Medical Technology UK 2025

 📍 Location: Coventry Building Society Arena

 👥 Meet Martin: 12-13 March


Let’s shape the future of medical technology and drug development together! 🔬💊


#Pharmidex #MedTechUK #DrugDiscovery #Innovation #Collaboration #MedicalTechnologyUK2025

🚀 Pharmidex at the R&D Society Life Science Workshop!

June 11, 2025
Pharmidex team are delighted to participate in workshop on "Re-shaping UK life science commercialisation strategy" organised by The Research and Development Society on Wednesday 11th June, at Mereside, Alderley Park. If you are attending, please linkup with our colleague Mo Alavijeh who will be delighted to meet you. Jamie Phadke , Alderley Park #UKlifescience https://lnkd.in/e6uKsRcN

🔬 Pharmidex at the 4th RSC Anglo-Nordic Medicinal Chemistry Symposium

June 10, 2025
Martin Barrett , Head of Business Development, will attend the symposium on 10–13 June 2025 at Hotel Comwell Borupgaard, Denmark. The event gathers top European scientists to discuss drug discovery. Martin looks forward to connecting with academia, CROs, and pharma to explore collaborations and showcase Pharmidex’s services from in silico to in vivo pharmacology. Attending? Let’s connect! 🔗 https://lnkd.in/ev7TW7WG

🔬 Pharmidex is proud to contribute to new research!

June 10, 2025
We’re excited to announce our involvement in the recent publication: "Anti-Inflammatory Activity of Ensifentrine: A Novel, Selective Dual Inhibitor of PDE3 and PDE4" 📄 https://pubmed.ncbi.nlm.nih.gov/40245851/ 📄 https://www.pharmidex.com/publications-by-pharmidex Dr. Radhakrishnan Venkatasamy , our Senior Scientist in autoinflammatory and immune diseases, co-authored this study highlighting Ensifentrine’s anti-inflammatory potential. This reflects Pharmidex’s commitment to advancing therapies through expert science and collaboration.
More Posts